Basilea Pharmaceutica Ag Allschwil

Bas­ilea Pharmaceutica’s strong governance, investor approval and focus on anti‑infective therapies make it a resilient biotech play poised for future growth.

Basilea Pharmaceutica AG has announced the commercial availability of its antibiotic Zevtera in the United States, marking a significant milestone for the company in addressing severe bacterial and fungal infections.